Sanofi has plucked a chief scientific officer for its global R&D operations out of the top ranks at the National Institutes of Health. The pharma giant is placing him at an office in Cambridge, MA, highlighting once again its high hopes of reinventing drug research inside the rich scientific environment found in the booming Massachusetts biotech hub.
Genzyme's manufacturing improvements continue to pay off, allowing it to return to the market with a full supply of its thyroid cancer treatment, Thyrogen.
A drug shortage has been solved. Genzyme is now able to supply its thyroid cancer treatment, Thyrogen, even as it moves further into thyroid cancer treatment with a new biomarker that helps doctors determine the need for surgery.
Sanofi's Genzyme group in Boston put up a new set of data to back its bid to make Lemtrada a leading therapy for multiple sclerosis.
The French drugmaker's decision to open a new Fabrazyme plant is responsible for one of the few bright spots on their Q3 earnings report.
Sanofi ($SNY) CEO Christopher Viebacher wants you to look past this quarter to better times ahead. "We are seeing the light at the end of the tunnel," Viehbacher told the media, after announcing that third-quarter profits weren't as low as expected (as quoted by Reuters). Net income dropped 7.4% to €2.22 billion ($2.9 billion), when analysts had projected, on average, €1.97 billion ($2.55 billion).
Alnylam revealed that the rare-disease specialists at Genzyme--the biologics arm of pharma giant Sanofi--had stepped in to license Asian rights to its program for ATTR, putting down $22.5 million as an upfront along with an unspecified lineup of milestones.
The tepid 9-6 vote from an FDA advisory panel left the new drug application looking relatively weak compared with a 13-2 vote for rival treatment lomitapide from Aegerion Pharmaceuticals.
Genzyme and its partners at Isis Pharmaceuticals ($ISIS) won a key endorsement today for mipomersen, an experimental therapy for homozygous familial hypercholesterolemia. But the tepid 9-6 outcome left the new drug application looking relatively weak compared with the 13-2 vote that greeted the rival drug lomitapide from Aegerion Pharmaceuticals yesterday.
This morning the regulatory and research team at Aegerion Pharmaceuticals were hunkered down preparing for Wednesday's FDA panel review of their new drug for rare cases of homozygous familial hypercholesterolemia, encouraged by an FDA review of lomitapide that focused considerable attention on the right kind of risk evaluation and mitigation strategy that could keep the risk/benefit profile in proper proportion.